Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Operations (2016 - 2025)

Neurocrine Biosciences' Cash from Operations history spans 16 years, with the latest figure at 388400000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 60.16% year-over-year to 388400000.0; the TTM value through Dec 2025 reached 782700000.0, up 31.46%, while the annual FY2025 figure was 782700000.0, 31.46% up from the prior year.
  • Cash from Operations reached 388400000.0 in Q4 2025 per NBIX's latest filing, up from 227500000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 388400000.0 in Q4 2025 to a low of 125200000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 118195000.0, with a median of 113350000.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: skyrocketed 3304.76% in 2022, then tumbled 209.14% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 4200000.0 in 2021, then surged by 3304.76% to 143000000.0 in 2022, then dropped by 13.64% to 123500000.0 in 2023, then skyrocketed by 96.36% to 242500000.0 in 2024, then soared by 60.16% to 388400000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Cash from Operations are 388400000.0 (Q4 2025), 227500000.0 (Q3 2025), and 102000000.0 (Q2 2025).